Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
12
ICU Quote, Financials, Valuation and Earnings
Last price:
$0.72
Seasonality move
:
-25.5%
Day range:
$0.59 - $0.68
52-week range:
$0.31 - $9.56
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
12.46x
Volume:
1.9M
Avg. volume:
13.1M
1-year change:
-91.44%
Market cap:
$7M
Revenue:
$135K
EPS (TTM):
-$3.47
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ICU
SeaStar Medical Holding
|
$200K | -- | 194.12% | -- | $7.00 |
|
GCTK
GlucoTrack
|
-- | -- | -- | -- | -- |
|
MBRX
Moleculin Biotech
|
-- | -- | -- | -- | $7.00 |
|
NBY
NovaBay Pharmaceuticals
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
PSTV
Plus Therapeutics
|
$1.5M | -$0.13 | -- | -68.08% | $9.17 |
|
TOVX
Theriva Biologics
|
-- | -$0.47 | -- | -95.63% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ICU
SeaStar Medical Holding
|
$0.66 | $7.00 | $7M | -- | $0.00 | 0% | -- |
|
GCTK
GlucoTrack
|
$5.92 | -- | $169.6M | -- | $0.00 | 0% | 6.90x |
|
MBRX
Moleculin Biotech
|
$0.84 | $7.00 | $11.8M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.65 | $0.85 | $3.8M | -- | $0.00 | 0% | 0.16x |
|
PSTV
Plus Therapeutics
|
$0.38 | $9.17 | $12.5M | -- | $0.00 | 0% | 0.63x |
|
TOVX
Theriva Biologics
|
$0.48 | $7.00 | $3.9M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ICU
SeaStar Medical Holding
|
39.12% | -1.046 | 2.36% | 0.77x |
|
GCTK
GlucoTrack
|
-- | -1.385 | -- | -- |
|
MBRX
Moleculin Biotech
|
-- | 0.045 | -- | -- |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | -0.044 | 1.51% | 0.75x |
|
PSTV
Plus Therapeutics
|
-- | -1.755 | -- | -- |
|
TOVX
Theriva Biologics
|
-- | -3.388 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ICU
SeaStar Medical Holding
|
$293K | -$3.8M | -- | -- | -1282.59% | -$2.7M |
|
GCTK
GlucoTrack
|
-- | -$3.5M | -- | -- | -- | -$2.9M |
|
MBRX
Moleculin Biotech
|
-- | -$5.9M | -- | -- | -- | -$4.6M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$2.7M | -334.47% | -461.38% | -44% | -$1.3M |
|
PSTV
Plus Therapeutics
|
-- | -$3.5M | -- | -- | -- | -$6.2M |
|
TOVX
Theriva Biologics
|
-- | -$4.4M | -- | -- | -- | -$4.8M |
SeaStar Medical Holding vs. Competitors
-
Which has Higher Returns ICU or GCTK?
GlucoTrack has a net margin of -1287.37% compared to SeaStar Medical Holding's net margin of --. SeaStar Medical Holding's return on equity of -- beat GlucoTrack's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ICUSeaStar Medical Holding-- -$0.44 $928K GCTKGlucoTrack-- -$40.20 -- -
What do Analysts Say About ICU or GCTK?
SeaStar Medical Holding has a consensus price target of $7.00, signalling upside risk potential of 952.79%. On the other hand GlucoTrack has an analysts' consensus of -- which suggests that it could fall by --. Given that SeaStar Medical Holding has higher upside potential than GlucoTrack, analysts believe SeaStar Medical Holding is more attractive than GlucoTrack.
Company Buy Ratings Hold Ratings Sell Ratings ICUSeaStar Medical Holding0 0 0 GCTKGlucoTrack0 0 0 -
Is ICU or GCTK More Risky?
SeaStar Medical Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GlucoTrack has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.622%.
-
Which is a Better Dividend Stock ICU or GCTK?
SeaStar Medical Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GlucoTrack offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SeaStar Medical Holding pays -- of its earnings as a dividend. GlucoTrack pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICU or GCTK?
SeaStar Medical Holding quarterly revenues are $293K, which are larger than GlucoTrack quarterly revenues of --. SeaStar Medical Holding's net income of -$3.8M is higher than GlucoTrack's net income of -$6.8M. Notably, SeaStar Medical Holding's price-to-earnings ratio is -- while GlucoTrack's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SeaStar Medical Holding is -- versus 6.90x for GlucoTrack. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICUSeaStar Medical Holding-- -- $293K -$3.8M GCTKGlucoTrack6.90x -- -- -$6.8M
-
Which has Higher Returns ICU or MBRX?
Moleculin Biotech has a net margin of -1287.37% compared to SeaStar Medical Holding's net margin of --. SeaStar Medical Holding's return on equity of -- beat Moleculin Biotech's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ICUSeaStar Medical Holding-- -$0.44 $928K MBRXMoleculin Biotech-- -$0.69 -- -
What do Analysts Say About ICU or MBRX?
SeaStar Medical Holding has a consensus price target of $7.00, signalling upside risk potential of 952.79%. On the other hand Moleculin Biotech has an analysts' consensus of $7.00 which suggests that it could grow by 737.72%. Given that SeaStar Medical Holding has higher upside potential than Moleculin Biotech, analysts believe SeaStar Medical Holding is more attractive than Moleculin Biotech.
Company Buy Ratings Hold Ratings Sell Ratings ICUSeaStar Medical Holding0 0 0 MBRXMoleculin Biotech1 0 0 -
Is ICU or MBRX More Risky?
SeaStar Medical Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moleculin Biotech has a beta of 1.381, suggesting its more volatile than the S&P 500 by 38.119%.
-
Which is a Better Dividend Stock ICU or MBRX?
SeaStar Medical Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moleculin Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SeaStar Medical Holding pays -- of its earnings as a dividend. Moleculin Biotech pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICU or MBRX?
SeaStar Medical Holding quarterly revenues are $293K, which are larger than Moleculin Biotech quarterly revenues of --. SeaStar Medical Holding's net income of -$3.8M is higher than Moleculin Biotech's net income of -$6.4M. Notably, SeaStar Medical Holding's price-to-earnings ratio is -- while Moleculin Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SeaStar Medical Holding is -- versus -- for Moleculin Biotech. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICUSeaStar Medical Holding-- -- $293K -$3.8M MBRXMoleculin Biotech-- -- -- -$6.4M
-
Which has Higher Returns ICU or NBY?
NovaBay Pharmaceuticals has a net margin of -1287.37% compared to SeaStar Medical Holding's net margin of -49.65%. SeaStar Medical Holding's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital ICUSeaStar Medical Holding-- -$0.44 $928K NBYNovaBay Pharmaceuticals65.26% $1.42 $1.1M -
What do Analysts Say About ICU or NBY?
SeaStar Medical Holding has a consensus price target of $7.00, signalling upside risk potential of 952.79%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 30.77%. Given that SeaStar Medical Holding has higher upside potential than NovaBay Pharmaceuticals, analysts believe SeaStar Medical Holding is more attractive than NovaBay Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings ICUSeaStar Medical Holding0 0 0 NBYNovaBay Pharmaceuticals1 0 0 -
Is ICU or NBY More Risky?
SeaStar Medical Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.
-
Which is a Better Dividend Stock ICU or NBY?
SeaStar Medical Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SeaStar Medical Holding pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICU or NBY?
SeaStar Medical Holding quarterly revenues are $293K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. SeaStar Medical Holding's net income of -$3.8M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, SeaStar Medical Holding's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SeaStar Medical Holding is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICUSeaStar Medical Holding-- -- $293K -$3.8M NBYNovaBay Pharmaceuticals0.16x -- $2.4M $7.7M
-
Which has Higher Returns ICU or PSTV?
Plus Therapeutics has a net margin of -1287.37% compared to SeaStar Medical Holding's net margin of --. SeaStar Medical Holding's return on equity of -- beat Plus Therapeutics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ICUSeaStar Medical Holding-- -$0.44 $928K PSTVPlus Therapeutics-- -$1.19 -- -
What do Analysts Say About ICU or PSTV?
SeaStar Medical Holding has a consensus price target of $7.00, signalling upside risk potential of 952.79%. On the other hand Plus Therapeutics has an analysts' consensus of $9.17 which suggests that it could grow by 2293.39%. Given that Plus Therapeutics has higher upside potential than SeaStar Medical Holding, analysts believe Plus Therapeutics is more attractive than SeaStar Medical Holding.
Company Buy Ratings Hold Ratings Sell Ratings ICUSeaStar Medical Holding0 0 0 PSTVPlus Therapeutics1 1 0 -
Is ICU or PSTV More Risky?
SeaStar Medical Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Plus Therapeutics has a beta of 0.693, suggesting its less volatile than the S&P 500 by 30.722%.
-
Which is a Better Dividend Stock ICU or PSTV?
SeaStar Medical Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SeaStar Medical Holding pays -- of its earnings as a dividend. Plus Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICU or PSTV?
SeaStar Medical Holding quarterly revenues are $293K, which are larger than Plus Therapeutics quarterly revenues of --. SeaStar Medical Holding's net income of -$3.8M is higher than Plus Therapeutics's net income of -$17.4M. Notably, SeaStar Medical Holding's price-to-earnings ratio is -- while Plus Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SeaStar Medical Holding is -- versus 0.63x for Plus Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICUSeaStar Medical Holding-- -- $293K -$3.8M PSTVPlus Therapeutics0.63x -- -- -$17.4M
-
Which has Higher Returns ICU or TOVX?
Theriva Biologics has a net margin of -1287.37% compared to SeaStar Medical Holding's net margin of --. SeaStar Medical Holding's return on equity of -- beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ICUSeaStar Medical Holding-- -$0.44 $928K TOVXTheriva Biologics-- -$1.55 -- -
What do Analysts Say About ICU or TOVX?
SeaStar Medical Holding has a consensus price target of $7.00, signalling upside risk potential of 952.79%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1367.51%. Given that Theriva Biologics has higher upside potential than SeaStar Medical Holding, analysts believe Theriva Biologics is more attractive than SeaStar Medical Holding.
Company Buy Ratings Hold Ratings Sell Ratings ICUSeaStar Medical Holding0 0 0 TOVXTheriva Biologics1 1 0 -
Is ICU or TOVX More Risky?
SeaStar Medical Holding has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 0.816, suggesting its less volatile than the S&P 500 by 18.373%.
-
Which is a Better Dividend Stock ICU or TOVX?
SeaStar Medical Holding has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SeaStar Medical Holding pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ICU or TOVX?
SeaStar Medical Holding quarterly revenues are $293K, which are larger than Theriva Biologics quarterly revenues of --. SeaStar Medical Holding's net income of -$3.8M is higher than Theriva Biologics's net income of -$4.3M. Notably, SeaStar Medical Holding's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SeaStar Medical Holding is -- versus 0.33x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ICUSeaStar Medical Holding-- -- $293K -$3.8M TOVXTheriva Biologics0.33x -- -- -$4.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
71
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
71
PGY alert for Jul 18
Pagaya Technologies [PGY] is up 3.8% over the past day.
Buy
68
MCRI alert for Jul 18
Monarch Casino & Resort [MCRI] is down 0.76% over the past day.
Sell
41
NEGG alert for Jul 18
Newegg Commerce [NEGG] is up 6.95% over the past day.
